The company has collected initial evidence for an algorithmic method to predict immunotherapy response, and is studying its technology in treatment monitoring.
Informaticians from Georgetown and other major cancer centers expect their technology to bring precision oncology services to community hospitals and clinics.
Data from more than 11,800 women with breast cancer suggested unselected BRCA1, BRCA2, and PALB2 testing is cost-effective for UK and US payors and societies.
The company operates three subsidiaries including Helomics, which provides tumor-analysis services for treatment personalization and new drug development.
